Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels.
Jansen L, de Niet A, Stelma F, van Iperen EP, van Dort KA, Plat-Sinnige MJ, Takkenberg RB, Chin DJ, Zwinderman AH, Lopatin U, Kootstra NA, Reesink HW. Jansen L, et al. Among authors: reesink hw. J Hepatol. 2014 Oct;61(4):730-7. doi: 10.1016/j.jhep.2014.05.004. Epub 2014 May 10. J Hepatol. 2014. PMID: 24824278
Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F, de Niet A, Tempelmans Plat-Sinnige MJ, Jansen L, Takkenberg RB, Reesink HW, Kootstra NA, van Leeuwen EM. Stelma F, et al. Among authors: reesink hw. J Infect Dis. 2015 Oct 1;212(7):1042-51. doi: 10.1093/infdis/jiv180. Epub 2015 Mar 19. J Infect Dis. 2015. PMID: 25791117
Peginterferon add-on: an added benefit?
Stelma F, Reesink HW. Stelma F, et al. Among authors: reesink hw. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):147-148. doi: 10.1016/S2468-1253(16)30220-5. Epub 2017 Jan 20. Lancet Gastroenterol Hepatol. 2017. PMID: 28404122 No abstract available.
Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S, van Nieuwkerk CMJ, Zaaijer HL, Molenkamp R, Takkenberg RB, Koot M, Verheij J, Beuers U, Reesink HW. de Niet A, et al. Among authors: reesink hw. Lancet Gastroenterol Hepatol. 2017 Aug;2(8):576-584. doi: 10.1016/S2468-1253(17)30083-3. Epub 2017 May 15. Lancet Gastroenterol Hepatol. 2017. PMID: 28522204 Clinical Trial.
Viral minority variants in the core promoter and precore region identified by deep sequencing are associated with response to peginterferon and adefovir in HBeAg negative chronic hepatitis B patients.
Jansen L, Welkers MRA, van Dort KA, Takkenberg RB, Lopatin U, Zaaijer HL, de Jong MD, Reesink HW, Kootstra NA. Jansen L, et al. Among authors: reesink hw. Antiviral Res. 2017 Sep;145:87-95. doi: 10.1016/j.antiviral.2017.07.013. Epub 2017 Jul 25. Antiviral Res. 2017. PMID: 28754258 Free article.
353 results